Canadian Nuclear Laboratories’ (CNL) Canadian Nuclear Research Initiative-Health Program (CNRI-H) is a program developed by CNL to further the realization of its mission of contributing to the health of Canadians. Through CNRI-H, CNL provides financial support1 along with its expertise, experience, capabilities and makes this available and accessible to the healthcare community to advance new life saving radiopharmaceutical solutions. CNRI-H is a turnkey solution that integrates both funding and project execution in one award.
The focus of the program is Radiopharmaceutical Therapy optimization, Toxicology and Pre-clinical Evaluation research. The goal of the program is to accelerate the optimization of therapeutic isotopes production and the clinical translation of targeted radiopharmaceuticals for the benefit of Canadians whilst increasing the safety and efficacy of therapies that involve radiopharmaceuticals.